Herpes zoster, Encephalopathy, Meningitis
Conditions
Interventions
None listed
Sponsors
Aisei Pharmacy Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with herpes zoster who were prescribed antiviral agents (amenamevir, acyclovir, valacyclovir, or famciclovir) Antiviral therapy lasting at least 7 days Adverse events (encephalopathy or herpes zoster exacerbation) occurring within 3 months after the first dose Availability of patient background information such as age, sex, and comorbidities
Exclusion criteria
Exclusion criteria: Patients who received antiviral therapy for indications other than herpes zoster. Lost to follow up Cases in which adverse event outcomes cannot be confirmed within 3 months after the initial prescription. Patients with a prior history of encephalopathy or meningitis before antiviral use. Cases in which adverse events are clearly attributable to other drugs. Patients receiving immunosuppressive agents. Patients with marked immunosuppression, such as those post bone marrow or organ transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of encephalopathy after antiviral drug administration based on the JADER database and pharmacy case data | — |
Secondary
| Measure | Time frame |
|---|---|
| Frequency of herpes zoster exacerbation Association of drug type, duration, and co-medications with encephalopathy onset Impact of differences in cerebrospinal fluid penetration on patient outcomes | — |
Countries
Japan
Contacts
Public ContactShingo Nemoto
Aisei Pharmacy Co., Ltd. Kanagawa Branch
Outcome results
None listed